Latest Shareholder Engagement News

Atlantic Lithium has locked in up to £28 million in funding from Long State Investments to advance its Ewoyaa Lithium Project in Ghana, navigating market challenges and permitting delays with financial flexibility.

Commonwealth Bank of Australia has updated details for its six-month dividend, confirming a fully franked payout of AUD 2.60 per share with multi-currency payment options and a Dividend Reinvestment Plan.

Carnegie Clean Energy is closing its Share Purchase Plan on 8 September, offering shareholders a discounted entry to fund key ocean energy projects. The capital raise aims to accelerate development in Europe, the US, and Australia.

Buru Energy has successfully raised $2.1 million through a share placement and launched a $3 million Share Purchase Plan to advance its Rafael Gas Project, targeting a Final Investment Decision by late 2026 and first cash flow by early 2028.

MAC Copper Limited shareholders convened pivotal meetings to vote on Harmony Gold's proposed acquisition, valuing MAC at over US$1 billion with a 20.7% premium. The outcome will reshape MAC's ownership and market presence.

Mad Paws Holdings has completed the divestment of its Pet Chemist business and announced the resignation of Executive Director Howard Humphreys, advancing its proposed acquisition by Rover Group.

Prestal Holdings reported a sharp 25% revenue decline and a staggering 133% increase in net loss for FY2025, yet still declared a special dividend and capital return.

Atlas Pearls Ltd has declared a fully franked 1.4 cent per share dividend for the second half of FY25, lifting total dividends for the year to 2.4 cents, up from 1.85 cents in FY24.

Ariadne Australia Limited reported a remarkable 409% jump in pre-tax profit for FY25, alongside a 38% revenue increase, yet faced a sharp decline in comprehensive income. The company declared a partially franked final dividend, signaling confidence amid mixed financial signals.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

WAM Research Limited reported a robust 22.4% growth in its investment portfolio for FY2025, outperforming key ASX indices and declaring a 10 cents per share dividend, partially franked at 60%. The company’s disciplined focus on undervalued growth stocks underpinned strong returns despite market volatility.

Proteomics International Laboratories reported a 26% increase in losses for FY2025, driven by higher operational costs as it advances its Promarker® diagnostic pipeline. Despite an 8% rise in revenue from ordinary activities, total income slipped 2%, underscoring ongoing commercialisation challenges.